Tapan M. Kadia

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Marina Konopleva, Daniel A. Pollyea, Jalaja Potluri et al. · Cancer Discovery · 2016 · 1.1K citations · Full text

Medicine, Hematology, Pharmacology +17

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

Naval Daver, Guillermo Garcia‐Manero, Sreyashi Basu et al. · Cancer Discovery · 2018 · 571 citations

Medicine, Oncology, Pharmacology +17

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Nitin Jain, Michael J. Keating, Philip A. Thompson et al. · New England Journal of Medicine · 2019 · 504 citations · Full text

Medicine, Hematology, Oncology +17

Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

Courtney D. DiNardo, Caitlin R. Rausch, Christopher B. Benton et al. · American Journal of Hematology · 2017 · 437 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

Hagop Kantarjian, Farhad Ravandi, Susan O’Brien et al. · Blood · 2010 · 399 citations · Full text

Medicine, Hematology, Oncology +16